Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well irinotecan hydrochloride,
oxaliplatin and cetuximab work in treating patients with unresectable or metastatic
pancreatic cancer. Irinotecan hydrochloride may stop the growth of tumor cells by blocking
some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin,
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as cetuximab, can block tumor growth
in different ways. Some block the ability of tumor to grow and spread. Others find tumor
cells and help kill them or carry tumor-killing substances to them. Giving irinotecan
hydrochloride together with oxaliplatin and cetuximab may kill more tumor cells.